Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder
- 4 March 2021
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 137 (9), 1260-1263
- https://doi.org/10.1182/blood.2020007555
Abstract
Epidemiological studies have demonstrated an increased incidence of MDS in patients with plasma cell disorder (PCD) i.e. multiple myeloma (MM) or MGUS and several case reports / series of co-occurring MDS and PCD have been published. The underlying pathogenesis for this condition, and if the two diseases share a common genetic lesion remains unknown. Here, we describe a cohort of 27 consecutive patients with co-occurring MDS and MM (n=6), MGUS (n=20) or plasmocytoma (n=1), diagnosed at the Karolinska University Hospital. In 5 patients, the diagnosis of MGUS preceded the diagnosis of MDS , in one patient the MDS diagnosis preceded PCD, and in 21 patients MDS and PCD were diagnosed at the same time. There was a preponderance for lower-risk MDS subgroups with only 3 patients belonging to the IPSS-R high / very high risk groups. Median overall survival for the whole cohort was 44 months. The most common mutations were TET2, SRSF2 and SF3B1. To identify potential common founder clones, we performed whole exome sequencing on isolated bone marrow myeloid-, plasma- and T-cells from 9 patients. In none of the patients, we could detect a common founder mutation and the two diseases have likely emerged from separate clones.This publication has 21 references indexed in Scilit:
- Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myelomaLeukemia Research, 2018
- Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCell Stem Cell, 2017
- Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyThe Lancet Oncology, 2016
- Myelodysplastic syndrome with 5q deletion following IgM monoclonal gammopathy, showing gene mutation MYD88 L265PBlood Cells, Molecules, and Diseases, 2015
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014
- Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In VivoCancer Cell, 2014
- Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen casesInternational Journal of Hematology, 2014
- Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patientsLeukemia, 2013
- Second malignancies after multiple myeloma: from 1960s to 2010sBlood, 2012
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Blood, 2011